Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01% — FDA update affecting Cosmetics & Personal-Care (MoCRA).
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on September 25, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics & Personal-Care (MoCRA) (indie beauty brands, contract manufacturers, private-label makers, importers/distributors) should confirm how it applies to their specific situation before acting. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
Who it affects
Cosmetics & Personal-Care (MoCRA) (indie beauty brands, contract manufacturers, private-label makers, importers/distributors)
What you must do
Read the update and assess whether your current setup needs to change.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
- Naveed Aslam: Final Debarment Order
- Jeffrey Thies: Final Debarment Order
- Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
- Connecticut Publishes Additional Information Regarding PFAS in Consumer Products Law - The National Law Review